Comparison of intraperitoneal with intravenous administration of taxol in experimental peritoneal carcinomatosis

Chemotherapy

Volumn 53, Issue 6, 2007, Pages 410-417

  Hribaschek, Arndt ^a   Meyer, Frank ^a   Schneider Stock, Regine ^a   Pross, Matthias ^a   Ridwelski, Karsten ^b   Lippert, Hans ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b Municipal Hospital   (Germany)

Author keywords

Chemotherapy; Peritoneal carcinomatosis; Taxol

Indexed keywords

ANTINEOPLASTIC AGENT; PACLITAXEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER TRANSPLANTATION; CARCINOMATOSIS; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; EXPERIMENTAL STUDY; MALE; NONHUMAN; PERITONEAL CAVITY; PERITONEUM TUMOR; POSTOPERATIVE CARE; PRIORITY JOURNAL; RAT; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DISEASE MODELS, ANIMAL; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; PACLITAXEL; PERITONEAL NEOPLASMS; RATS; RATS, INBRED ACI; RATS, INBRED STRAINS;

EID: 36048989939     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110005     Document Type: Article

References (32)

1. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-914.
2. Salgado M, Firvida J, Mata J, Vasquez S, et al: A phase II study of weekly taxol combinated with folinic acid and 5-FU in pretreated colorectal cancer (CRC) patients (abstract 296a). Proc Am Soc Clin Oncol 2000;19:1157.
3. Markman M: Intraperitoneal paclitaxel in the management of ovarian cancer. Semin Oncol 1995;22:86-87.
4. Markman M, Rowinsky E, Hakes T, Jones W, Lewis JL Jr, Rubin S, Curtin J, Barakat R, Phillips M, et al: Phase I trial of intraperitoneal taxol. J Clin Oncol 1992;10:1485-1491.
5. Cass AW, Million RR, Pfaff WW: Patterns of recurrence following surgery alone for adenocarcinoma of the colon and rectum. Cancer 1976;37:2861-2865.
6. Malcolm AW, Perencevich NP, Olson RM, Hanley JA, Chaffey JT, Wilson RE: Analysis of recurrence patterns following curative resection for carcinoma of the colon and rectum. Surg Gynecol Obstet 1981;152:131-136.
7. Michelassi F, Vannucci L, Ayala JJ, Chappel R, Goldberg R, Block GE: Local recurrence after curative resection of colorectal cancer. Surgery 1990;108:787-793.
8. Pescatori M, Mattana C, Maria G, Ferrara A, Lucibello L: Outcome of colorectal cancer. Br J Surg 1987;74:370-372.
9. Phillips RK, Hittinger R, Blesovsky L, Fry JS, Fielding LP: Local recurrence following 'curative' surgery for large bowel cancer. 1. The overall picture. Br J Surg 1984;71:12-16.
10. Stipa S, Nicolanti V, Botti C, Cosimelli M, Mannella E, Stipa F, Giannarelli D, Bangrazi C, Cavaliere R: Local recurrence after curative resection of colorectal cancer: frequency, risk factors and treatment. J Surg Oncol 1991;2(suppl):155-160.
11. Willet CG, Tepper JE, Cohen AM, Orlow E, Welch CE: Failure patterns following curative resection of colonic carcinoma. Ann Surg 1984;200:685-690.
12. Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC: Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 1989;63:364-367.
13. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, Francois Y, Vignal J, Gilly FN: Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88:358-363.
14. Bokemeyer C, Hartmann JT, Lampe CS, Clemens MR, Quietzsch D, Forkmann L, Kanz L: Paclitaxel and weekly 24-hour infusion of 5-fluoruracil/folinic acid in advanced gastric cancer. Semin Oncol 1997;24(suppl 19):S19-S96;S19-S100.
15. Liggins RT, D'Amours S, Demetrick JS, Machan LS, Burt HM: Paclitaxel loaded poly(L-lactic acid) microspheres for the prevention of intraperitoneal carcinomatosis after a surgical repair and tumor cell spill. Biomaterials 2000;21:1959-1969.
16. Pross M, Lippert H, Mantke R, Kruger S, Gunther T, Marusch F, Halangk W, Schulz HU: A proteinase inhibitor decreases tumor growth in a laparoscopic rat model. Surg Endosc 2001;15:882-885.
17. Sugarbaker PH, Yonemura Y: Palliation with a glimmer of hope: management of resectable gastric cancer with peritoneal carcinomatosis. Hepatogastroenterology 2001;48:1238-1247.
18. Stein HJ, Kraemer SJM, Feussner H, Siewert JR: Clinical value of diagnostic laparoscopy with laparoscopic ultrasound in patients with cancer of the esophagus or cardia. J Gastrointest Surg 1997;1:167-173.
19. Maruyama M, Takamatsu S, Sugano N, Ebuchi M, Endo M, Yuasa Y: Experimental study on intraperitoneal sequential MTX/5-FU therapy for peritoneal seeding in comparison with intravenous administration. Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 1997;24:2131-2136.
20. Scheithauer W, Kornek GV, Marczell A, Karner J: Combined intravenous and intraperitoneal chemotherapy with 5-FU + leucovorin vs 5-FU + levamisole for adjuvant therapy of resected colon carcinoma. Br J Cancer 1998;77:1349-1354.
21. Shiu M, Fortner J: Intraperitoneal hyperthermic treatment of implanted peritoneal cancer in rats. Cancer Res 1980;40:4081-4084.
22. Benoit L, Duvillard C, Beltramo JL, Brunet-Lecomte P, Chauffert B: Intraperitoneal cisplatin plus epinephrine and surgical debulking for the treatment of advanced peritoneal carcinomatosis in the rat. Gastroenterol Clin Biol 2000;24:26-30.
23. Sugarbaker PH, Jablonski KA: Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995;221:124-132.
24. Hagiwara A, Takahashi T, Kojima O, Sawai K, Yamaguchi T, Yamane T, Taniguchi H, Kitamura K, Noguchi A, Seiki K, et al: Prophylaxis with carbon-absorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 1992;339:629-631.
25. Yu W, Whang I, Suh I, Averbach A, Chang D, Sugarbaker PH: Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 1998;228:347-354.
26. Horsell KW, Merten S, Clingan P, King DW, Morris DL: Peritonectomy and intraperitoneal chemotherapy in appendiceal and colorectal cancer. Aust N Z J Surg 1999;69:729-732.
27. Fass J, Jansen M, Zengel K, Reinecke T, Asshoff G, Schumpelick V: Results of intraperitoneal active charcoal-mitomycin C therapy of stomach carcinoma with serosa invasion. Langenbecks Arch Chir Suppl Kongressbd 1998;115(suppl):1363-1366.
28. Sautner T, Hofbauer F, Depisch D, Schiessel R, Jakesz R: Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 1994;12:970-974.
29. Rosen HR, Jatzko G, Repse S, Potrc S, Neudorfer H, Sandbichler P, Zacherl J, Rabl H, Holzberger P, Lisborg P, Czeijka M: Adjuvant intraperitoneal chemotherapy with carbon-absorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian working group for surgical oncology. J Clin Oncol 1998;16:2733-2738.
30. Samel S, Singal A, Becker H, Post S: Problems with intraperitoneal chemotherapy for advanced gastric cancer. Eur J Surg Oncol 2000;26:222-226.
31. Grivicich I, Regner A, da Rocha AB, Kayser GB, Schunemann DP, Grass LB, Alves PAG, Henriques JAP, Schwartsmann G: The irinotecan/ 5-fluorouracil combination induces apoptosis and enhances manganese superoxide dismutase activity in HT-29 human colon carcinoma cells. Chemotherapy 2005;51:93-102.
32. Mishima H, Kato T, Yanagisawa M, Tsujinaka T, Nishisho I, Tsujie M, Fujimoto-Ouchi K, Tanaka Y, Kikkawa N: Sequential treatment with irinotecan and doxifluridine: optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer. Chemotherapy 2005;51:32-39.